{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:08:53Z","timestamp":1775488133759,"version":"3.50.1"},"reference-count":9,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,11,25]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Serum sickness (SS) is a known phenomenon; however, it is commonly missed due to vague symptoms, and is usually confounded by other aetiologies that present similarly. Obinutuzumab is a novel anti-CD20 antibody agent that has been approved for chronic lymphocytic leukaemia (CLL) treatment. At the time of approval, it was not linked to SS; however, this phenomenon has been recognised with other anti-CD20 agents like rituximab. SS remains a rare entity, but it is important to be recognised accurately and quickly in the appropriate circumstances, so that effective treatment with corticosteroids can be initiated to alleviate inflammatory symptoms. Here we present a patient with CLL who developed maculopapular rash, fever and polyarthritis and elevated inflammatory markers consistent with serum sickness triggered by obinutuzumab and was effectively treated with corticosteroids.<\/jats:p>","DOI":"10.1136\/bcr-2021-245557","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T12:02:10Z","timestamp":1640174530000},"page":"e245557","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia"],"prefix":"10.1136","volume":"14","author":[{"given":"Oday","family":"Elmanaseer","sequence":"first","affiliation":[{"name":"Internal Medicine, Albany Medical Center, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alzira R M","family":"Avelino","sequence":"additional","affiliation":[{"name":"Internal Medicine, Albany Medical Center, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Azem","sequence":"additional","affiliation":[{"name":"Internal Medicine, Albany Medical Center, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihir","family":"Raval","sequence":"additional","affiliation":[{"name":"Hematology, New York Oncology and Hematology, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"2025082713022037000_14.12.e245557.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"2025082713022037000_14.12.e245557.2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/14740338.2016.1165665","article-title":"Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations","volume":"15","author":"Reda","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2025082713022037000_14.12.e245557.3","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"2025082713022037000_14.12.e245557.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198411293112204"},{"key":"2025082713022037000_14.12.e245557.5","doi-asserted-by":"publisher","DOI":"10.1177\/120347540000400411"},{"key":"2025082713022037000_14.12.e245557.6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ccr3.969","article-title":"Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia","volume":"5","author":"Saba","year":"2017","journal-title":"Clin Case Rep"},{"key":"2025082713022037000_14.12.e245557.7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00431-012-1926-y","article-title":"Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions","volume":"172","author":"Zhang","year":"2013","journal-title":"Eur J Pediatr"},{"key":"2025082713022037000_14.12.e245557.8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-Induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2025082713022037000_14.12.e245557.9","doi-asserted-by":"crossref","DOI":"10.1378\/chest.1958613","article-title":"Plasmapheresis reverses ARDS in rituximab induced serum sickness","volume":"146","author":"Manko","year":"2014","journal-title":"Chest"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-245557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T20:02:29Z","timestamp":1756324949000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-245557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":9,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,22]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bcr-2021-245557"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-245557","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}